Health
Sleep Apnea
FDA Approves First-Ever Drug Treatment for Obstructive Sleep Apnea
2 sources · 18d ago
Factlen Deep Dive
First Patient Achieves Sustained Insulin Independence Following Autologous Stem Cell-Derived Islet Transplant
3 sources · 18d ago
Factlen Deep Dive
First Patient Achieves Sustained Insulin Independence Following Autologous Stem Cell-Derived Islet Transplant
3 sources · 18d ago
More in Health
Factlen ExplainerRespiratory Health
A Single Injection Is Replacing Steroids for Severe Asthma and COPD Attacks
Respiratory Researchers 39%Patient Advocacy Groups 39%Clinical Practitioners 22%
5 sources · 18d ago
Factlen ExplainerRespiratory Health
A Single Injection Is Replacing Steroids for Severe Asthma and COPD Attacks
Respiratory Researchers 39%Patient Advocacy Groups 39%Clinical Practitioners 22%
5 sources · 18d ago
Longevity ScienceExplainer
Landmark Study Finds Tiny, Combined Tweaks to Sleep, Diet, and Exercise Add Years to Life
Preventative Medicine Advocates 40%Public Health Pragmatists 40%Methodological Skeptics 20%
4 sources · 18d ago
Factlen ExplainerPediatric Oncology
Landmark CAR-T Trial Achieves Complete Tumor Elimination in Child With Previously Incurable Brain Cancer
Clinical Trial Investigators 39%Cellular Engineering Researchers 33%Pediatric Cancer Advocates 28%
5 sources · 18d ago
Factlen ExplainerPediatric Oncology
Landmark CAR-T Trial Achieves Complete Tumor Elimination in Child With Previously Incurable Brain Cancer
Clinical Trial Investigators 39%Cellular Engineering Researchers 33%Pediatric Cancer Advocates 28%
5 sources · 18d ago
Factlen ExplainerAlzheimer's Disease
The Evidence Pack: How the FDA-Approved Antibody Donanemab is Rewriting Alzheimer's Treatment
Clinical Researchers 47%Patient Advocacy Groups 35%Healthcare Economists 18%
6 sources · 18d ago
Factlen ExplainerAlzheimer's Disease
The Evidence Pack: How the FDA-Approved Antibody Donanemab is Rewriting Alzheimer's Treatment
Clinical Researchers 47%Patient Advocacy Groups 35%Healthcare Economists 18%
6 sources · 18d ago
Factlen ExplainerAddiction Policy
US Health Programs Mandated to End Harm Reduction Focus in New Federal Overdose Policy
Federal Administration & Recovery Advocates 35%Public Health & Harm Reduction Organizations 35%State & Local Implementers 30%
4 sources · 18d ago
Factlen ExplainerOncology Breakthrough
Landmark Immunotherapy Trial Achieves 33% Three-Year Survival in Previously Untreatable MSS Colorectal Cancer
Clinical Oncologists 40%Immunology Researchers 35%Patient Advocates & Ethicists 25%
4 sources · 18d ago
Factlen ExplainerOncology Breakthrough
Landmark Immunotherapy Trial Achieves 33% Three-Year Survival in Previously Untreatable MSS Colorectal Cancer
Clinical Oncologists 40%Immunology Researchers 35%Patient Advocates & Ethicists 25%
4 sources · 18d ago
Heart HealthExplainer
Landmark 10-Year Study Finds Irregular Bedtimes Double Risk of Heart Attack and Stroke
Chronobiologists & Sleep Researchers 40%Cardiologists & Clinical Practitioners 40%Public Health Advocates 20%
6 sources · 18d ago
Factlen ExplainerOrexin Agonists
First-in-Class Orexin Agonist Oveporexton Shows Significant Improvement in Wakefulness for Narcolepsy Type 1 in Landmark Phase 3 Trials
Sleep Medicine Researchers 41%Patients & Advocacy Groups 35%Industry Analysts 24%
4 sources · 18d ago
Factlen ExplainerChildhood Anxiety
The Evidence Pack: How the SPACE Program is Equipping Parents to Reverse Childhood Anxiety
Clinical Researchers 40%Public Health Officials 30%Family Therapists 30%
5 sources · 18d ago
Factlen ExplainerChildhood Anxiety
The Evidence Pack: How the SPACE Program is Equipping Parents to Reverse Childhood Anxiety
Clinical Researchers 40%Public Health Officials 30%Family Therapists 30%
5 sources · 18d ago
Factlen ExplainerMotor Neurone Disease
How a New Drug Targeting the C5aR2 Receptor Could Turn Motor Neurone Disease Into a Chronic Condition
Structural Biologists 35%Patient Advocacy Groups 35%Clinical Neurologists 30%
2 sources · 18d ago
Factlen ExplainerMotor Neurone Disease
How a New Drug Targeting the C5aR2 Receptor Could Turn Motor Neurone Disease Into a Chronic Condition
Structural Biologists 35%Patient Advocacy Groups 35%Clinical Neurologists 30%
2 sources · 18d ago
Factlen ResearchPsychiatric Care
The Evidence Pack: How the WHO's New Initiative Aims to Close the Schizophrenia Mortality Gap
Public Health Officials 40%Psychiatric Clinicians 35%Patient Advocacy Groups 25%
5 sources · 18d ago
Factlen ResearchPsychiatric Care
The Evidence Pack: How the WHO's New Initiative Aims to Close the Schizophrenia Mortality Gap
Public Health Officials 40%Psychiatric Clinicians 35%Patient Advocacy Groups 25%
5 sources · 18d ago
Fungal PathogensExplainer
WHO Launches Global Blueprint to Combat Rising Fungal Diseases and Antifungal Resistance
Public Health Officials 40%Clinical Mycologists 35%One Health Advocates 25%
4 sources · 18d ago
Factlen ExplainerLung Cancer Therapy
Landmark Trial: Bispecific Antibody Ivonescimab Achieves 34% Survival Advantage Over Standard Immunotherapy in Lung Cancer
Clinical Oncologists 40%Biopharma Analysts 35%Evidence Skeptics 25%
4 sources · 19d ago
Factlen ExplainerLung Cancer Therapy
Landmark Trial: Bispecific Antibody Ivonescimab Achieves 34% Survival Advantage Over Standard Immunotherapy in Lung Cancer
Clinical Oncologists 40%Biopharma Analysts 35%Evidence Skeptics 25%
4 sources · 19d ago
Genomic TestingTreatment De-escalation
Landmark Phase 3 Trial Shows Genomic Test Safely Spares Two-Thirds of High-Risk Breast Cancer Patients from Chemotherapy
Clinical Oncologists 40%Patient Advocates 30%Health System Researchers 30%
5 sources · 19d ago
Factlen ExplainerBundibugyo Virus
WHO Launches Landmark Global Trial to Find First Effective Treatments for Bundibugyo Virus
Global Health Authorities 35%Clinical Researchers 35%Frontline Responders 29%
5 sources · 19d ago